Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.56 |
| ▸ | APLNR | P35414 | 4/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947727 | 1.00 | PDE2A (0.56) | PDE2AAPLNRDGAT1LMNATP53 | |
| SCHEMBL16043191 | 1.00 | PDE2A (0.56) | PDE2AAPLNRDGAT1LMNATP53 | |
| SCHEMBL30263811 | 1.00 | PDE2A (0.56) | PDE2AAPLNRDGAT1LMNATP53 | |
| Hydrochloric Acid SCHEMBL4984670 | 0.98 | PDE2A (0.55) | PDE2AAPLNRDGAT1LMNATP53 | |
| Hydrochloric Acid SCHEMBL12498663 | 0.98 | PDE2A (0.55) | PDE2AAPLNRDGAT1LMNATP53 | |
| SCHEMBL14987514 | 0.83 | PDE2A (0.43) | PDE2AAPLNRDGAT1LMNATP53 | |
| SCHEMBL18449424 | 0.83 | PDE2A (0.43) | PDE2AAPLNRDGAT1LMNATP53 | |
| SCHEMBL20238210 | 0.83 | PDE2A (0.43) | PDE2AAPLNRDGAT1LMNATP53 | |
| SCHEMBL30169618 | 0.83 | APLNR (0.50) | PDE2AAPLNRDGAT1LMNAKDM1A | |
| SCHEMBL2550576 | 0.83 | APLNR (0.50) | PDE2AAPLNRDGAT1LMNAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-115867554-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| CN-1333769-A | Thiourea inhibitors of herps viruses | AMERICAN HOME PROD (US) | 2002-01-30 | — | — | CN | disclosed |
| CN-1332725-A | Thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-01-23 | — | — | CN | disclosed |
| US-6335350-B1 | VARICELLA-ZOSTER, HUMAN CYTOMEGALO, EPSTEIN-BARR AND KAPOSI HERPESVIRUS TREATMENT | AMERICAN HOME PRODUCTS CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6271236-B1 | PHENYL UREAS/THIOUREAS AS INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE ENZYME, USEFUL IN TREATING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, AND VARICELLA-ZOSTER VIRUS | WYETH | 2001-08-07 | — | — | US | disclosed |
| US-6262082-B1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | WYETH | 2001-07-17 | — | — | US | disclosed |
| US-6262090-B1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6207715-B1 | USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-27 | — | — | US | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6197803-B1 | VIRICIDES; PREVENTION REPRODUCTION | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | PDE2A 4599/4885APLNR 4331/4885DGAT1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.